This was a fully decentralized, longitudinal, open-label study to evaluate the effect on QoL factors in participants with the common cold using a nasal spray containing xylometazoline hydrochloride 0.1% in a real-world setting across the United Kingdom. No randomization was carried out in this study. The design of this study is not specific to any of the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network guidelines.